Onsdag 8 Oktober | 21:45:35 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2025-11-07 08:00 Kvartalsrapport 2025-Q3
2025-08-19 - Kvartalsrapport 2025-Q2
2025-05-22 - X-dag ordinarie utdelning SCIB 0.00 SEK
2025-05-21 - Årsstämma
2025-05-13 - Kvartalsrapport 2025-Q1
2025-02-25 - Bokslutskommuniké 2024
2024-12-13 - Extra Bolagsstämma 2024
2024-11-12 - Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-06-14 - X-dag ordinarie utdelning SCIB 0.00 SEK
2024-06-13 - Årsstämma
2024-05-31 - Kvartalsrapport 2024-Q1
2024-02-22 - Bokslutskommuniké 2023
2023-11-10 - Kvartalsrapport 2023-Q3
2023-08-18 - Kvartalsrapport 2023-Q2
2023-05-19 - X-dag ordinarie utdelning SCIB 0.00 SEK
2023-05-17 - Årsstämma
2023-05-10 - Kvartalsrapport 2023-Q1
2023-02-13 - Bokslutskommuniké 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning SCIB 0.00 SEK
2022-05-18 - Årsstämma
2022-05-12 - Kvartalsrapport 2022-Q1
2022-02-23 - Bokslutskommuniké 2021
2021-11-11 - Kvartalsrapport 2021-Q3
2021-09-07 - Extra Bolagsstämma 2021
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-19 - X-dag ordinarie utdelning SCIB 0.00 SEK
2021-05-18 - Årsstämma
2021-05-12 - Kvartalsrapport 2021-Q1
2021-02-19 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-06-17 - Årsstämma
2020-05-15 - X-dag ordinarie utdelning SCIB 0.00 SEK
2020-05-05 - Kvartalsrapport 2020-Q1
2020-04-29 - Extra Bolagsstämma 2020
2020-02-21 - Bokslutskommuniké 2019
2019-11-13 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-17 - X-dag ordinarie utdelning SCIB 0.00 SEK
2019-05-16 - Årsstämma
2019-05-10 - Kvartalsrapport 2019-Q1
2019-02-20 - Bokslutskommuniké 2018
2018-11-13 - Kvartalsrapport 2018-Q3
2018-08-20 - Kvartalsrapport 2018-Q2
2018-05-17 - X-dag ordinarie utdelning SCIB 0.00 SEK
2018-05-16 - Årsstämma
2018-05-09 - Kvartalsrapport 2018-Q1
2018-02-20 - Bokslutskommuniké 2017
2017-11-15 - Extra Bolagsstämma 2017
2017-11-10 - Kvartalsrapport 2017-Q3
2017-08-18 - Kvartalsrapport 2017-Q2
2017-05-17 - X-dag ordinarie utdelning SCIB 0.00 SEK
2017-05-16 - Årsstämma
2017-05-10 - Kvartalsrapport 2017-Q1
2017-02-17 - Bokslutskommuniké 2016
2016-11-14 - Kvartalsrapport 2016-Q3
2016-08-19 - Kvartalsrapport 2016-Q2
2016-05-17 - X-dag ordinarie utdelning SCIB 0.00 SEK
2016-05-16 - Årsstämma
2016-05-13 - Kvartalsrapport 2016-Q1
2016-02-19 - Bokslutskommuniké 2015
2015-11-12 - Kvartalsrapport 2015-Q3
2015-08-20 - Kvartalsrapport 2015-Q2
2015-05-06 - Kvartalsrapport 2015-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
SciBase Holding är en global medicinteknisk koncern specialiserad på diagnostisk och prevention inom dermatologi. Bolaget utvecklar, producerar och kommersialiserar Nevisense, en patientnära plattform som kombinerar AI (artificiell intelligens) med EIS-teknik för att möjliggöra tidig upptäckt och intervention av hudcancer och andra hudsjukdomar. Nevisense är baserad på över 20 års forskning vid Karolinska Institutet, huvudkontoret ligger i Stockholm.
2025-09-23 08:00:00

SWEDEN - September 23, 2025 - SciBase Holding AB ("SciBase") [STO: SCIB], a leader in AI-based devices for detection and prevention in dermatology, today announces that it has received the initial order for a clinical study under the collaboration with Castle Biosciences. The order consists of Nevisense Go and electrodes to a value of around $0.8 million or approximately MSEK 8.

As previously announced on June 16th, 2025, SciBase has entered into a collaboration and license agreement with Castle Biosciences (Nasdaq: CSTL), a US-based leader in molecular diagnostics. The initial collaboration project is to develop a test that predicts flares in patients diagnosed with atopic dermatitis (AD). This order is for products to be used in a clinical study for the first project. Deliveries will start in Q4.

Following the signing of the collaboration agreement, Castle has also invested in SciBase and is now SciBase second largest shareholder.

"The collaboration with Castle Biosciences is moving forward at a fast pace and this first order signals the initiation of our first joint study," said Pia Renaudin, CEO of SciBase. "At SciBase we are very excited to, together with Castle Biosciences, help patients with skin barrier dysfunctions get access to more effective therapies."

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CEST on September 23, 2025.

For additional information, please contact:

Pia Renaudin, CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.com

Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: certifiedadviser@carnegie.se

About SciBase  
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ).  Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases